AN2 Therapeutics (ANTX) Profit After Tax (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Profit After Tax for 6 consecutive years, with -$10.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 5.1% year-over-year to -$10.1 million; the TTM figure through Mar 2026 stood at -$34.5 million (up 23.36% YoY), while the FY2025 annual figure was -$35.1 million, up 31.51% from the prior year.
• Profit After Tax eased to -$10.1 million in Q1 2026 per ANTX's latest filing, from -$8.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$6.5 million in Q2 2025 and bottomed at -$17.2 million in Q4 2023.
• Historically, Profit After Tax has averaged -$11.9 million across 5 years, with a median of -$11.3 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax slumped 273.78% — and 2024, when it jumped 57.09%.
• AN2 Therapeutics' Profit After Tax stood at -$11.8 million in 2022, then slumped by 44.82% to -$17.2 million in 2023, then surged by 57.09% to -$7.4 million in 2024, then dropped by 17.52% to -$8.6 million in 2025, then slipped by 16.67% to -$10.1 million in 2026.
• Business Quant data shows ANTX's Profit After Tax at -$10.1 million in Q1 2026, -$8.6 million in Q4 2025, and -$9.3 million in Q3 2025.